RBP2 and chronic myelogenous leukemia, BCR-ABL1 positive: RBP2 increases CML resistance to TKIs and shifts CML to the acute phase.133 In addition, the activated AKT pathway can activate testis-specific Y-encoded-like protein 5 (TSPYL5) and prevent its ubiquitination and subsequent degradation.